Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3FXYD2
The experimentally established mechanism targets of Lanatoside C. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 12/20 | 0.71 |
| ▸ | ATP1B1 known ✓ | P05026 | 12/20 | 0.71 |
| ▸ | ATP1A2 known ✓ | P50993 | 12/20 | 0.71 |
| ▸ | ATP1B2 known ✓ | P14415 | 11/20 | 0.71 |
| ▸ | ATP1B3 known ✓ | P54709 | 11/20 | 0.71 |
| ▸ | ATP1A3 known ✓ | P13637 | 1/20 | 0.71 |
| ▸ | FXYD2 known ✓ | P54710 | 1/20 | 0.71 |
| ▸ | ATP1A4 known ✓ | Q13733 | 1/20 | 0.71 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.89 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | STAT3 | P40763 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | RORC | P51449 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanatoside C SCHEMBL18947801 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL20582682 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL18277653 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL18364709 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL44110 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL23054706 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL15959375 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| SCHEMBL18949552 | 0.97 | PAX8 (0.94) | PAX8LMNATP53SMN1; SMN2THRB | |
| SCHEMBL24837992 | 0.97 | PAX8 (0.94) | PAX8LMNATP53SMN1; SMN2THRB | |
| SCHEMBL20251039 | 0.97 | PAX8 (0.94) | PAX8LMNATP53SMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062417-A1 | CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4567102-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AVIAN EMBRYONIC CELLS | Suprême (FR) | 2025-06-11 | — | — | EP | disclosed |
| CN-119745907-A | Application of ouabain C in preparation of medicine for treating prostatic cancer | 上海市生物医药技术研究院 | 2025-04-04 | — | — | CN | disclosed |
| CN-118047825-A | Preparation method of desacetyl erigeron glycoside | 威智医药股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-113999276-B | Purification method and preparation method of desacetyl erigeron glycoside intermediate | 威智医药股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4215195-A1 | LANATOSIDE C, CLOPIDOGREL, AND R406 IN TREATMENT OF CVD-CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CVD-CHIP) | Genome Biologics UG (DE) | 2023-07-26 | — | — | EP | disclosed |
| US-20230086722-A1 | METHODS FOR ANALYSIS OF TARGET MOLECULES IN BIOLOGICAL FLUIDS | Grail, Inc. | 2023-03-23 | — | — | US | disclosed |
| WO-2023006961-A1 | LANATOSIDE C IN TREATMENT OF CVD-CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CVD-CHIP) | GENOME BIOLOGICS UG (DE) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022023380-A2 | ASSAY | KING'S COLLEGE LONDON (GB) | 2022-02-03 | — | — | WO | disclosed |
| CN-113999276-A | Purification method and preparation method of deacetyl hairy flower glycoside intermediate | 威智医药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3897657-A2 | <SUP2/>? <SUB2/>?+? ?NA/K <NS1:SUP>+</NS1:SUP>?ATPASE INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS | Universität Basel (CH) | 2021-10-27 | — | — | EP | disclosed |
| US-20200325543-A1 | DIAGNOSTIC METHOD | TOLREMO THERAPEUTICS AG (CH) | 2020-10-15 | — | — | US | disclosed |
| WO-2020127943-A2 | NA+/K+ ATPASE INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS | UNIVERSITÄT BASEL (CH) | 2020-06-25 | — | — | WO | disclosed |
| CN-108982739-A | The detection method of reversed-phased high performace liquid chromatographic inspection Lanatoside C standard substance | 上海佰年诗丹德检测技术有限公司 | 2018-12-11 | — | — | CN | disclosed |
| US-20160331771-A1 | Treatment of Hyperproliferative Disorders Using Cardiac Glycosides | COMGENRX, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062417-A1 | CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR | BTK, SYK, LYN | ATP1A1 3053/4885ATP1B1 3369/4885ATP1A2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.